Scroll To Top
Search by Speciality

PROSTATE CANCER WORLD CONGRESS INCORPORATING 14TH AUSTRALASIAN PROSTATE CANCER CONFERENCE

Melbourne Convention and Exhibition Centre # | Melbourne, AUSTRALIA
From 90 to 4279 AUD
Event Preview
EXPIRED
This event
is Finished
Title: PROSTATE CANCER WORLD CONGRESS INCORPORATING 14TH AUSTRALASIAN PROSTATE CANCER CONFERENCE
Specialty: , Medical Oncology, Urology
Dates: From Aug, 6, 2013 to Aug, 10, 2013
Location: Melbourne, AUSTRALIA
Type: Conference, Congress
Registration Cost: From 90 to 4279 AUD
Event Tools
  • Add to Favorites
  • Claim this event
Add to my Calendar
Aug
Weather Info (monthly averages) Max Temperature: C / F Min Temperature: C / F The above data in our Weather Info table are temperature predictions for the date of the medical event for Melbourne, Australia.
General Info
Event Venue:

Melbourne Convention and Exhibition Centre #

Melbourne, AUSTRALIA
Recognised as Australiasia's Leading Meetings and Conference Centre in 2014, 2013 and 2012 by the prestigious World Travel Awards, Melbourne Convention and Exhibition Centre connects you with everything you need for a successful event. This includes amazing spaces, leading technology, creative food and wine and staff with the skills and experience to bring it all together.
Visit the Venue to read more
Currency:
AUD
Event Overview
Welcome message:

On behalf of the Organising Committee, we would like to invite you to the Prostate Cancer World Congress incorporating the 14th Australasian Prostate Cancer Conference. Bringing together world leaders presenting their expertise and current research on all areas of prostate cancer.

The Prostate Cancer World Congress will present an outstanding Faculty featuring leading International guest presenters and a selection of talented and recognised experts. World leading opinion leaders will come together to share and discuss all aspects of prostate cancer diagnosis and management delivering presentations and workshops to fully update us on the latest developments in prostate cancer.

 

This year's International Faculty includes:

  • Dr Thomas Ahlering, Professor & Vice Chairman Department of Urology University of California, Irvine School of Medicine, USA
  • Dr William J Catalona, Department of Urology, Chicago, USA
  • Prof Noel Clarke, Professor of Urological Oncology, Manchester University, UK
  • Dr Matthew Cooperberg, A/Prof, Depts of Urology & Epidemiology & Biostatistics, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center USA
  • Dr Martin Gleave, British Columbia Leadership Chair, Professor and Distinguished University Scholar, Department of Urologic Sciences, University of British Columbia, Director, The Vancouver Prostate Centre, Canada 
  • Dr Larry Goldenberg, University of British Columbia, Canada
  • Dr Makarand V Khochikar, Siddhi Vinayak Ganapati Cancer Hospital, Miraj, India
  • Dr Stacy Loeb, Assistant Professor of Urology and Population Health, New York University, USA
  • Dr Vipul Patel, Director of Robotic Surgery, Professor of Urology, UCF, Director of Urologic Oncology, Florida Hospital Cancer Institute, USA
  • Dr Tom Pickles, BC Cancer Agency, Canada
  • Dr Monique Roobol, Erasmus University Medical Center, Department of Urology, Rotterdam, The Netherlands 
  • Dr Oliver Sartor, Tulane University School of Medicine, USA
  • Dr Joseph A Smith, Professor and Chairman, Department of Urologic Surgery, Vanderbilt University, Nashville USA
  • Dr Matthew Smith, Harvard Medical School, USA
  • Dr Rainy Umbas, Asian School of Urology, Indonesia
  • Dr Patrick C Walsh, University Distinguished Service Professor, The James Buchanan Brady Urological Institute, Johns Hopkins Medicine, USA.

 

The program includes specialised parallel meetings for Clinical Urology, Translational Science, Nursing and Allied Health and General Practiceand will ensure the most comprehensive information and presentations specifically to your area of expertise within prostate cancer management and care.

The unfortunate fact for men is that there is still enormous uncertainty about prostate cancer and we need a far greater investment and collaboration in research to improve care for men affected. It is as important today, as it ever has been, for researchers, clinicians and industry to come together to further prostate cancer discovery and care. 

Please contact

Kind regards,
Prof Anthony Costello 
President 
Prostate Cancer World Congress


Professor Anthony Costello
Executive Director, Australian Prostate Cancer Research
Director of Urology, Royal Melbourne Hospital

Speakers/Faculty:

This year's International Faculty includes:

  • Dr Thomas Ahlering, Professor & Vice Chairman Department of Urology University of California, Irvine School of Medicine, USA
  • Dr William J Catalona, Department of Urology, Chicago, USA
  • Prof Noel Clarke, Professor of Urological Oncology, Manchester University, UK
  • Dr Matthew Cooperberg, A/Prof, Depts of Urology & Epidemiology & Biostatistics, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center USA
  • Dr Martin Gleave, British Columbia Leadership Chair, Professor and Distinguished University Scholar, Department of Urologic Sciences, University of British Columbia, Director, The Vancouver Prostate Centre, Canada 
  • Dr Larry Goldenberg, University of British Columbia, Canada
  • Dr Makarand V Khochikar, Siddhi Vinayak Ganapati Cancer Hospital, Miraj, India
  • Dr Stacy Loeb, Assistant Professor of Urology and Population Health, New York University, USA
  • Dr Vipul Patel, Director of Robotic Surgery, Professor of Urology, UCF, Director of Urologic Oncology, Florida Hospital Cancer Institute, USA
  • Dr Tom Pickles, BC Cancer Agency, Canada
  • Dr Monique Roobol, Erasmus University Medical Center, Department of Urology, Rotterdam, The Netherlands 
  • Dr Oliver Sartor, Tulane University School of Medicine, USA
  • Dr Joseph A Smith, Professor and Chairman, Department of Urologic Surgery, Vanderbilt University, Nashville USA
  • Dr Matthew Smith, Harvard Medical School, USA
  • Dr Rainy Umbas, Asian School of Urology, Indonesia
  • Dr Patrick C Walsh, University Distinguished Service Professor, The James Buchanan Brady Urological Institute, Johns Hopkins Medicine, USA.

 

Dr Thomas E. Ahlering, M.D. Professor of Urology and Vice ChairmanDepartment of Urology, University of California, USA

Dr. Ahlering received a B.S. in Chemistry from the University of California, Berkeley (1975) his M.D. at St. Louis University (1979) and residency in urology at the University of Southern California (1984) and fellowship in urologic oncology at USC under Dr. Donald Skinner and Peter Jones Ph.D (1986).  From 1986-1992 Dr. Ahlering headed the Department of Urologic Oncology at the City of Hope and from 1992-2002 was Chief of the Division of Urology at the University of California, Irvine.  In 2002 Dr. Ralph Clayman became Chairman and Dr. Ahlering - Vice Chairman.  Dr. Ahlering has active research projects in prostate cancer, and has produced over 150 publications of journal articles and book chapters. 

 

Dr William J Catalona, Department of Urology, Chicago, USA

Dr. Catalona joined the Northwestern faculty in 2003. He is known for having been the first to show that a simple blood test that measures levels of prostate-specific antigen (PSA) is the most accurate method for detecting prostate cancer and for having developed the "free" PSA test as a means of improving the accuracy of prostate cancer screening.

Dr. Catalona is currently conducting research into the genetics of prostate cancer which could lead to new tests for the disease as well as possible new means of treating or preventing prostate cancer. He specializes in prostate cancer surgery and is recognized as an expert in performing the "nerve-sparing" radical prostatectomy that can preserve sexual potency.

In addition to his appointment as Professor of Urology, Dr. Catalona also serves as Director of the Clinical Prostate Cancer Program of Northwestern's Robert H. Lurie Comprehensive Cancer Center.

 

Prof Noel Clarke, ChM  FRCS (Urol), Professor of Urological Oncology, Manchester University, UK

Qualified 1981 (Lond). Consultant Urological Surgeon 1993-. Specialist in Urological Cancer and complex pelvic and retroperitoneal tumours.

Formerly: Director Urology/Surgery Salford Royal and Christie Hospitals, Chairman Greater Manchester Urological Cancer Network, Chair UK NCRI Prostate Clinical Studies Group from 2003 to 2009.  Currently: Professor of Urological Oncology, Manchester University, Director Manchester University GU Cancer Research Group, director pan-Manchester MCRC biobank. Member UK Department of Health Prostate Cancer and the NCRN advisory boards, Deputy Chair EORTC GU Group, faculty member European School Urology.

Research encompassing basic science, translational studies, multiple Phase 2 / 3 trials in Urological Cancer. Multiple peer reviewed papers and book chapters on Urology and Urological cancer.

 

Dr Matthew Cooperberg, A/Prof, Depts of Urology & Epidemiology & Biostatistics, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center USA

Matthew Cooperberg completed his undergraduate education at Dartmouth College and his medical and public health degrees at Yale University. He then completed his residency in urology and fellowship and urologic oncology at UCSF under Peter Carroll. He has multiple research interests, focusing in particular prostate cancer, and has published over 100 peer-reviewed publications in this area. His current areas of particular interest include biomarker validation, comparative effectiveness of treatment for localized prostate cancer, and evolving practice patterns for advanced disease. He maintains busy surgical practices at the UCSF Cancer Center and the San Francisco VA medical center, and lives in San Francisco with his family.

 

 

Dr Martin Gleave, British Columbia Leadership Chair, Professor and Distinguished University Scholar, Department of Urologic Sciences, University of British Columbia, Director, The Vancouver Prostate Centre, Canada 

Dr Martin Gleave is a Distinguished Professor and Vice Chair of the Department of Urologic Sciences at the University of British Columbia (UBC), Director of the Vancouver Prostate Center, and a BC Leadership Chair.  He has published > 340 papers with >14,000 citations, has an H-Index of 68, and attracted >$80M in research funding.

Dr. Gleave’s research characterizes molecular mechanisms mediating treatment resistance in cancer, focusing on stress-activated adaptive responses that drive acquired treatment resistance, and designing rational combination co-targeting strategies to create conditional lethality and improve cancer control. He patented several anti-cancer drugs and in 2001 founded OncoGenex Pharmaceuticals to develop OGX-011, an inhibitor of the cell survival gene, clusterin, that potentiates anti-cancer therapies in many cancer models. A randomized trial demonstrated a 7 month gain in overall survival when OGX-011 was combined with docetaxel and 2 Phase III registration trials with OGX-011 are open.  OGX-427 is another agent targeting Hsp27 that has demonstrated single agent activity in Phase II studies of castrate resistant prostate cancer, and bladder cancer.

 

Dr. Stacy Loeb, Assistant Professor of Urology and Population Health, New York University, NY, USA

Dr. Stacy Loeb is an Assistant Professor of Urology and Population Health at New York University (NYU), specializing in prostate cancer.  Dr. Loeb attended medical school at Northwestern University and completed her urology residency training at Johns Hopkins.  She has published over 150 peer-reviewed articles and 8 book chapters on prostate cancer.  She is on the Editorial Board for the British Journal of Urology International and Reviews in Urology, and authored the chapter on “Early Detection, Diagnosis, and Staging of Prostate Cancer” for Campbell-Walsh Urology.  Dr. Loeb also helps teach several courses on prostate cancer for other urologists, and hosts the Men’s Health Show on Sirius XM 81 satellite radio.

 

Dr Vipul Patel, Director of Robotic Surgery, Professor of Urology, UCF, Director of Urologic Oncology, Florida Hospital Cancer Institute, USA

 

Dr. Patel attended medical school at Baylor College of Medicine, and did both his residency and fellowship training at the University of Miami. Prior to moving to Florida he was Director of Robotic and Minimally Invasive Urologic Surgery at The Ohio State University.

Yearly, Dr Patel trains hundreds of surgeons on how to safely adopt robotic technology into their surgical practices and leads the robotic training team at the Nicholson Center for Surgical Advancement. He Chairs the World Robotic Symposium, an annual premiere event in robotic surgical education. He is also founder of the Society of Robotic Surgery a multi-specialty organization responsible for education and training.

He is Editor in Chief of The Journal of Robotic Surgery and editor of the first robotic urology textbook. His interests are minimally invasive approaches to the treatment of prostate and kidney cancer, focusing on prostate cancer outcomes. He has performed over 5000 robotic prostatectomies and leads one of the worlds most experienced surgical teams.

 

Dr Joseph A Smith, Professor and Chairman, Department of Urologic Surgery, Vanderbilt University, Nashville USA

Joseph A Smith, Jr. is Professor and Chairman of the Department of Urologic Surgery at Vanderbilt University in Nashville, Tennessee.  He is an AOA graduate of the University of Tennessee Medical School and was chosen the Outstanding Graduate.  He performed his surgery residency at the University of Texas Southwestern Medical School at Dallas, his urology residency at the University of Utah, and a fellowship in urologic oncology at Memorial Sloan-Kettering Cancer Center in New York. 

Dr Smith has served as President of the American Board of Urology, President of the Society of Urologic Oncology, President of the Southeastern Section of the American Urologic Association, and Chairman of the Residency Review Committee for Urology. He is a recipient of the Distinguished Contribution Award and the Hugh Hampton Young Award from the American Urologic Association and the SUO achievement medal from the Society of Urologic Oncology.  He is Associate Editor of the Journal of Urology and is a member of the American Association of Genitourinary Surgeons and the Clinical Society of GU Surgeons.

He has published over 300 peer reviewed manuscripts, over 100 book chapters, and has edited or co-edited eight textbooks. His professional focus has been on innovative treatment strategies for patients with urologic cancers and introduction and evaluation of technologic advances in urologic surgery.

 

Dr Patrick C Walsh, University Distinguished Service Professor, The James Buchanan Brady Urological Institute, Johns Hopkins Medicine, USA

Dr. Walsh is best known for his pioneering work in the development of nerve-sparing radical prostatectomy, which has reduced the probability of impotence and incontinence. He is on the editorial board of the New England Journal of Medicine, is a member of the Institute of Medicine of the National Academy of Sciences, and in 1996 he received the Charles F. Kettering Medal from the General Motors Cancer Research Foundation for “the most outstanding recent contributions to the diagnosis and treatment of cancer.” Together with Janet F. Worthington, he authored the best-selling book for lay people Dr. Patrick Walsh’s Guide to Surviving Prostate Cancer, (Hachette Book Group (2012). 

 

 

 

 

 

 

Registration Not yet available Register Now
Accommodation
Accommodation:

The Congress Office can coordinate your accommodation requirements. Attractive rates have been negotiated for delegates and a range of accommodation options are on offer near the conference venue. The following hotels can be booked via the registration form. All rates quoted are per room per night, inclusive of GST and do not include breakfast unless otherwise stated.

 

Further Details:

ICMS Travel, as the official housing bureau for the Congress, has been able to secure discounted accommodation rates at various hotels in Melbourne. The room rates are per night and do not include breakfast, unless specified. Accommodation will be allocated in order of receipt of bookings and payment.

Arrival Time
Check-in time is usually from 14:00. Should you wish to guarantee your room is ready before the hotel check-in time it is recommended that you book and pay for the room for the evening prior to your arrival. Failure to advise your arrival time may mean that your room will be released.

Deposit
To secure your accommodation booking ,credit card detail are required to be supplied as a guarantee of your arrival. These details need to be supplied on the online registration form prior to entering your accommmodation details. Your credit card details will be passed onto the hotel to secure your booking. Please be aware that a one night's deposit may be processed by the property prior to your arrival alternatively the property may charge your accommdoation in full at the conclusion of your stay. This will be at the discretion of the property booked. Bookings cannot be made until ICMS Travel receives your credit card details. Room rates are in Australian Dollars and include the Australian Goods and Services Tax (GST)

Scientific Content Up to Date
Submission Info

Oral and poster presentations will be accepted from all fields of prostate cancer and may be invited to be included in the PCWC Program.

MONENTARY PRIZES WILL BE AWARDED TO THE BEST ABSTRACT IN THE FOLLOWING CATEGORIES 

 

  • Clinical Urology
  • Translational Science
  • Nursing & Allied Health
Editorial Guidelines for Presented Content:

The Program committee invites abstract submissions from all facets of the prostate cancer care delivery for admission into the program for 2013.

Authors are requested to review the instructions and on the abstract submission portal before preparing and submitting an abstract.

Moderated poster presentations and selected oral presentations will be offered in the Clinical Urology, Translational Science and Nursing & Allied Health streams. The General Practice stream will not accept moderated poster presentations.

The Program committee will only communicate via email with the nominated contact for the moderated poster submission; therefore it is imperative that the details given in the address for correspondence section are accurate. It is expected that the contact person will communicate the outcome of the moderated poster submission with all authors.

It is a requirement that the nominated presenter is registered for the Congress. 

Abstracts must be submitted by 9 April, 2013 and presented in English. Text should be entered in upper and lower case. Please do not type Abstract titles or text all in capital letters. 

The abstract should include objective, methods results and conclusions. Conclusions of the form – “Results will be discussed” – are not acceptable. Only standard abbreviations may be used.

Abstracts submitted for presentation will be published exactly as submitted. Copy should be checked for accuracy and misspelling prior to submission.

Please do not send multiple submissions of the same abstract. To enable you to edit and access your abstract before the submission deadline, please note your abstract submission number and password.

To enter or edit your abstract, proceed to the online form CLICK HERE to submit your Abstract

Sponsors Exhibitors
General Info

We are expecting over 1000 prostate cancer practitioners representing Clinical Urology, Translational Science, Nursing & Allied Health and General Practice to come together to the largest and most comprehensive prostate cancer educational event held in the world.

Exhibition Floor plans
Contact
Organising Agency

ICMS Pty Ltd
PO Box 170
Hawthorn VIC 3122
T: +61 1300 792 466
F: +61 3 9818 7111
Email: pcwc2013@icms.com.au

 

Locked Bag LB10
East Melbourne VIC 8002
Phone: +61 3 9421 0985
Fax: +61 3 9429 8470
Email: info@apcr.org.au
Web: http://www.apcr.org.au

Event map
Revelant Events